Table 2.
Characteristics of patients with or without observed initiation of BOT (categorical variables)
| Covariate | Total population | BOT(observed) | BOT(not observed) | p-value |
|---|---|---|---|---|
| (N = 31,008) | (N = 6,705) | (N = 24,303) | ||
| n (%) | n (%) | n (%) | ||
| Gender | ||||
| Male | 16,728 (53.9) | 3,698 (55.2) | 13,030 (53.6) | 0.026 |
| Female | 14,280 (46.1) | 3,007 (44.8) | 11,273 (46.4) | |
| Microvascular diseasesa | ||||
| Yes | 10,851 (35.0) | 2,643 (39.4) | 8,208 (33.8) | <0.0001 |
| No | 20,157 (65.0) | 4,062 (60.6) | 16,095 (66.2) | |
| Macrovascular diseases | ||||
| Yes | 7,377 (23.8) | 1,711 (25.5) | 5,666 (23.3) | <0.001 |
| No | 23,631 (76.2) | 4,994 (74.5) | 18,637 (76.7) | |
| Hypoglycaemia | ||||
| Yes | 86 (0.3) | 36 (0.5) | 50 (0.2) | <0.0001 |
| No | 30,922 (99.7) | 6,669 (99.5) | 24,253 (99.8) |
Legend: BOT basal supported oral therapy. Test for independence between groups by means of Fisher’s exact tests
aPatient and/or physician reported data